AKT inhibitors synergize with agents that suppress the histone methyltransferase EZH2 and promote robust tumour regression in multiple triple-negative breast cancer models in vivo by triggering an involution-like process.
- Amy E. Schade
- Naiara Perurena
- Karen Cichowski
